Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up Iron deficiency (ID) is an important comorbidity in heart failure (HF). 1 Its reported prevalence in chronic heart failure (CHF) is 30-50% and it constitutes an independent predictor of morbidity, mortality and cardiac transplantation. 2, 3 Current European Society of Cardiology (ESC) guidelines for the diagnosis and management of acute and chronic HF recommend assessment of iron parameters in symptomatic HF patients with reduced ejection fraction, with ensuing iron therapy in cases of ID, as defined by the criteria used in the FAIR-HF (Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure) trial.
1,4 Data on ID in acutely decompensated HF (ADHF) are scarce, yet in the CardioFer study, conducted in 865 patients in France, ID showed a higher prevalence in ADHF patients (60-80%). 5 In this study, we performed serial blood sampling in ADHF patients and assessed the reliability of ID diagnosis during ADHF. In addition, we wanted to evaluate the associations between parameters of iron metabolism and biomarkers of inflammation, cardiovascular stress, fibrosis and renal function. Patients were derived from the Biomarcoeurs cohort (ClinicalTrials.gov: NCT 01374880), detailed previously. 6 This substudy included patients with decompensated CHF and de novo HF. Patients with a concomitant infection or myocardial ischaemia were excluded. The protocol of the study was approved by the local ethics committee and patients provided written informed consent. Following admission, blood sampling was performed at day 0 (D0) and day 30 (D30). Iron status was assessed in several ways: we considered absolute and functional ID as defined by the ESC 1 thus: ID was considered to be absolute if serum ferritin was <100 μg/L, and functional when serum ferritin was 100-299 μg/L and transferrin saturation (TSAT) was <20%. Furthermore, we assessed plasma levels of hepcidin and soluble transferrin receptor (sTfR) and defined ID as represented by serum hepcidin of <14.5 ng/mL (5th percentile among healthy controls; depleted iron stores) and/or sTfR of ≥1.59 mg/L (95th percentile among healthy controls; depleted intracellular iron content in metabolizing cells). 7 Several biomarkers were analysed, including brain natriuretic peptide (BNP), mid-regional-proadrenomedullin (MRproADM), procalcitonin (PCT), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), growth/differentiation factor-15 (GDF15), galectin-2, fibrinogen, soluble ST2, tumour necrosis factor-(TNF-) and myeloperoxidase (MPO). Statistical analyses were performed using STATA version 14. Forty-seven ADHF patients (32 men and 15 women) in whom assessments of ferritin and TSAT had been made at both D0 and D30 were included (data are available in supplementary material online, Tables S1 and S2). Their age (mean ± standard deviation) was 70.4 ± 13.7 years. Median BNP was 1004 pg/mL [interquartile range (IQR): 652-1676 pg/mL]. At D0, the median ferritin value was 93 μg/L (IQR: 76-107 μg/L) and median TSAT was 13% (IQR: 6-20%). Twenty-seven (57%) patients fulfilled criteria for absolute ID and 12 (26%) patients did so for functional ID. Thus, 83% of ADHF patients fulfilled the criteria for ID at admission.
At D30 of follow-up and guideline-based treatments, the median ferritin value was found to have increased to 159 μg/L (IQR: 134-190 μg/L; P < 0.0001), median TSAT was 17% (IQR: 12-23%; P = 0.0176), and median BNP was 261 pg/mL (IQR: 176-462 pg/mL; P < 0.0001). Frequencies of absolute and functional ID were 11% (five patients) and 57% (27 patients), respectively. The remaining 15 patients (32%) were not ID at D30 of follow-up. Iron status changed significantly between D0 and D30 (P = 0.00001). The difference between the absence and presence of ID is clinically more important than the difference between absolute and functional ID; therefore, absolute and functional ID were combined for the purpose of comparing overall prevalences of ID between D0 and D30, which showed a trend toward statistical significance (P = 0.07) ( Figure 1A) and only a moderate association between ID status at D0 and D30 ( coefficient: 0.26).
Circulating levels of hepcidin and sTfR were available for 41 patients at D0; 34 (83%) patients were identified as ID. Comparisons of ID status at D0 using either ferritin/transferrin or hepcidin/sTfR criteria are presented in Figure 1B . Twenty-eight patients (68%) were similarly categorized by both definitions, 13 patients (32%) were considered to be ID according to one but not the other definition. Based on our subsample of 41 patients, there was no difference between these iron parameters in sensitivity to detect ID at admission (P = 0.78); further analysis revealed a weak association between both tests ( coefficient: 0.04).
To explain the variation in ferritin and TSAT in parallel with adequate treatment of ADHF, we correlated the iron parameters studied with several cardiovascular and inflammatory biomarkers. ΔFerritin (ferritin at D30 minus ferritin at D0) correlated with Δsoluble ST2 (Spearman's = −0.4028; P = 0.0082) and ΔIL-6 ( = −0.3569; P = 0.0138), but not with ΔMR-proADM, ΔBNP, ΔPCT, ΔTNF-, ΔhsCRP, ΔGDF15, Δgalectin-3, Δfibrinogen or ΔMPO. ΔTransferrin saturation correlated only with Δgalectin-3 ( = −0.3858; P = 0.0074). We did not detect a correlation between Δhepcidin or ΔsTfR and the other biomarkers studied.
In conclusion, biochemical evidence of ID is common at admission for ADHF. Transferrin saturation and ferritin increase significantly over a period of 30 days following ADHF admission, which changes the ID status of patients significantly between D0 and D30 following ADHF. Thus, iron status is not stationary in ADHF patients, even during short periods of follow-up. Changing levels of circulating markers of inflammation weakly correlated with changing circulating iron parameters, which supports the suggestion that systemic inflammation contributes to alterations in iron status between admission and steady state. By contrast, changing iron ................................................................................................................................................................................................................   ........................................................................................................................................................................................................... 
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